$VKTX, $GPCR, $SKYE: three clinical-stage obesity stocks chasing the next generation of weight-loss drugs

Quick snapshot: the three names in focus

All three are U.S.-listed, tradeable clinical-stage developers, but they sit at very different points on the risk-reward curve. Viking is the most advanced (already in Phase 3) and the best-known. Structure is the best-capitalized oral bet, with a balance sheet that removes near-term financing pressure. Skye is a differentiated micro-cap where the mechanism is the story — and where the tight cash position makes financing risk as important as clinical risk. The sections below go through each in depth, then place them against the broader field.

Why obesity became the biggest theme in biotech

To understand why investors treat clinical-stage obesity names as high-stakes lottery tickets, it helps to understand the size of the prize and the biology behind it. Obesity affects a very large share of the adult population in the United States and many other developed markets, and it is linked to a long list of costly comorbidities: type 2 diabetes, cardiovascular disease, obstructive sleep apnea, metabolic-associated liver disease (MASH) and more. For decades, pharmacological weight loss was modest and often came with tolerability or safety problems. The arrival of highly effective incretin-based therapies changed that.

The modern wave began with GLP-1 receptor agonists. GLP-1 (glucagon-like peptide-1) is a gut hormone that stimulates insulin secretion, slows gastric emptying and acts on appetite centers in the brain to reduce food intake. Semaglutide (Novo Nordisk’s Wegovy/Ozempic) demonstrated that a once-weekly GLP-1 agonist could produce roughly 15% mean weight loss in obesity trials — a figure previously associated mainly with bariatric surgery. That reset expectations for the entire field.

The next step added a second hormone. GIP (glucose-dependent insulinotropic polypeptide) is another incretin, and combining GLP-1 with GIP activity (as in Eli Lilly’s tirzepatide, sold as Zepbound and Mounjaro) pushed mean weight loss into the roughly 20%+ range in its pivotal program. Tirzepatide effectively raised the efficacy bar that every new entrant is now measured against. This is why the mechanism of each pipeline drug matters so much: the market wants to know not just “does it work,” but “does it work as well as or better than tirzepatide, and with what tolerability and dosing convenience.”

Beyond GLP-1 and GIP, several additional mechanisms are shaping the next generation:

• Glucagon. Adding glucagon-receptor activity (as in Lilly’s retatrutide, Altimmune’s pemvidutide and Boehringer/Zealand’s survodutide) can increase energy expenditure and may help with liver-fat reduction, at the cost of more complex metabolic effects that trials must characterize carefully.
• Amylin. Amylin analogs (such as Novo’s cagrilintide and Zealand/Roche’s petrelintide) work through a different satiety pathway and are being developed both alone and in combination with GLP-1, with the hope of strong weight loss and gentler gastrointestinal tolerability.
• Non-incretin pathways. Some developers are betting on mechanisms entirely outside the gut-hormone family — for example the endocannabinoid CB1 receptor (Skye’s nimacimab). The appeal is a differentiated, potentially complementary mechanism; the challenge is that this space has a difficult history (the withdrawn CB1 blocker rimonabant), which is exactly why a peripherally-restricted approach that avoids the brain is the core of the modern thesis.

Finally, there is the oral versus injectable axis. Most approved high-efficacy drugs are injectables. A convenient, high-efficacy oral pill could dramatically expand the treatable population and ease manufacturing and cold-chain constraints. That is exactly why oral programs — Lilly’s orforglipron, Novo’s oral semaglutide and amycretin, Structure’s aleniglipron and Viking’s oral VK2735 — attract so much attention. The prize is not only efficacy; it is efficacy in a pill. With that framework in place, here are the three names in detail.

Comparison: three different risk profiles on one radar

The three names map three distinct points on the biotech risk-reward curve. $VKTX is the most advanced and the most liquid, with the reward and the risk concentrated in a pivotal Phase 3 readout. $GPCR pairs strong Phase 2 oral data with a balance sheet that removes near-term financing pressure, making it more of an execution-and-competition story than a survival story. $SKYE is the differentiated wildcard, where a novel mechanism and an interesting combination signal sit alongside a missed monotherapy endpoint and a genuine cash constraint. Same theme, three very different bets.

The rest of the in-research field (context)

The three names above are the focus, but they compete inside a crowded and fast-moving pipeline. Understanding the surrounding field is essential to reading each stock, because a rival’s data can reset the benchmark overnight. Here are the other notable in-research programs — several of them owned by large caps, which is exactly why they belong in the background rather than in the core of a trader-focused radar.

Amgen — MariTide (maridebart cafraglutide) · large cap

Amgen’s MariTide is one of the most-watched next-generation candidates. It is engineered to block the GIP receptor while activating the GLP-1 pathway (a different design philosophy from the GLP-1/GIP agonist combinations), and it is built for infrequent dosing — potentially monthly or even less frequent. Amgen has advanced MariTide into a Phase 3 program (the MARITIME studies), including trials in obesity and in obesity with type 2 diabetes, plus additional cardiometabolic settings. MariTide is not approved and its outcome will be an important read-through for the whole class. As a mega-cap program inside a diversified company, though, it is competitive context for the pure-plays rather than a clean small-cap trade.

Zealand Pharma / Roche — petrelintide · partnered

Petrelintide is a long-acting amylin analog for once-weekly subcutaneous dosing, developed by Zealand Pharma in a global collaboration with Roche. It is arguably the single most valuable non-mega-cap obesity asset because of the amylin mechanism’s promise of strong weight loss with gentler GI tolerability. In Phase 2 (ZUPREME-1), petrelintide showed dose-dependent efficacy of up to 10.7% mean body-weight reduction at 42 weeks versus 1.7% for placebo, with favorable GI tolerability. Zealand and Roche announced in April 2026 that they would advance petrelintide to Phase 3 for chronic weight management, and they also plan a Phase 2 trial of a petrelintide plus CT-388 (enicepatide) fixed-dose combination. The catch for U.S. traders: Zealand is primarily a Danish-listed stock, so it is less directly tradeable than the U.S.-listed pure-plays — strong for the science, weaker as a cashtag.

Novo Nordisk — amycretin (zenagamtide), CagriSema · large cap

Novo Nordisk, already a commercial leader, has a deep next-generation pipeline. CagriSema is a fixed-dose combination of the amylin analog cagrilintide and semaglutide (the REDEFINE program). Amycretin — now referred to as zenagamtide — is a single-molecule GLP-1 and amylin receptor agonist being developed in both oral and subcutaneous forms; Novo reported roughly 22% weight loss with weekly injectable amycretin over 36 weeks in an early-stage study and has moved it toward a Phase 3 program. These are competitive-context assets inside a mega-cap, not stand-alone trades.

Eli Lilly — retatrutide · large cap

Retatrutide is Lilly’s triple agonist (GLP-1, GIP and glucagon), sometimes nicknamed the “triple G.” It has produced some of the highest weight-loss figures reported in the class: the pivotal Phase 3 TRIUMPH-1 trial was reported to meet its endpoints with an average weight loss of about 28.3% at 80 weeks, and a large share of patients on the top dose achieving 30% or more weight loss. Lilly has guided that it expects to complete the Phase 3 program in late 2026 or early 2027, enabling regulatory submission. Retatrutide is a key reason the efficacy bar keeps rising — and another mega-cap benchmark the pure-plays are measured against.

Altimmune — pemvidutide · obesity now a secondary focus

Altimmune’s pemvidutide is a GLP-1/glucagon dual agonist that produced roughly 15.6% mean weight loss at the top dose at 48 weeks in its Phase 2 MOMENTUM obesity trial, with a body-composition profile the company highlights for lean-mass preservation (about 21.9% of weight loss from lean mass, 78.1% from fat). Altimmune completed an end-of-Phase 2 FDA meeting for obesity and designed a Phase 3 obesity program. However, the company has increasingly emphasized MASH (metabolic-associated steatohepatitis, a liver indication) as a lead priority, with a Phase 3 PERFORMA trial planned. Because obesity now sits alongside — rather than clearly ahead of — the liver program in Altimmune’s strategy, we treat $ALT here as a background player rather than a pure obesity bet.

Others investors track

The broader field also includes Roche’s CT-388 (enicepatide), a GLP-1/GIP asset central to its combination strategy with petrelintide; Boehringer Ingelheim’s survodutide (a GLP-1/glucagon dual agonist developed with Zealand, pursued in obesity and MASH); and Rhythm Pharmaceuticals ($RYTM), whose setmelanotide is focused on rare genetic forms of obesity rather than the broad population. Not every one of these is a clean, tradeable pure-play, but together they show how crowded the pipeline has become — and why any single readout has to be judged against a moving competitive benchmark.

The approved drugs that set the bar (context)

You cannot read the clinical-stage names without knowing what they must beat. The approved landscape is anchored by two companies, and their products define efficacy, tolerability and convenience expectations for everything in the pipeline.

Novo Nordisk — semaglutide franchise

Novo Nordisk pioneered the modern GLP-1 obesity market with semaglutide: Wegovy for chronic weight management and Ozempic for type 2 diabetes (with Rybelsus as an oral semaglutide tablet in diabetes). Semaglutide established roughly 15% mean weight loss as the reference point for a once-weekly GLP-1. Novo has extended the franchise with an oral semaglutide option for weight management and, in 2026, a higher-dose injectable, Wegovy HD (semaglutide 7.2 mg), which the company reported delivered about 20.7% mean weight loss in its STEP UP trial — pushing Novo’s own ceiling higher and narrowing the gap to tirzepatide.

Eli Lilly — tirzepatide and the first any-time oral pill

Eli Lilly’s tirzepatide (Zepbound for obesity, Mounjaro for diabetes) is the current efficacy benchmark among widely available injectables, having delivered weight loss in the roughly 20%+ range in its pivotal program by combining GLP-1 and GIP activity. In 2026 Lilly added a landmark oral option: orforglipron, branded Foundayo, which the FDA approved on April 1, 2026. Orforglipron is a once-daily oral small-molecule GLP-1 agonist and is notable as the first GLP-1 pill that can be taken any time of day without food or water restrictions — a real convenience differentiator versus oral semaglutide’s stricter dosing requirements. In its ATTAIN-1 obesity trial, the top dose produced about 12.4% weight loss (roughly 27.3 lbs) at 72 weeks.

The strategic message for the pure-plays is clear. The bar is high and still rising: tirzepatide and the newest higher-dose semaglutide define injectable efficacy, while orforglipron and oral semaglutide define the oral race that Structure and Viking’s oral tablet are trying to enter. Any new entrant has to justify its place either on efficacy, on tolerability, on dosing convenience, on formulation (a pill), or on a differentiated mechanism — which is exactly the lens through which to read $VKTX, $GPCR and $SKYE.

How to keep these three on the operational radar

Each name rewards watching a different thing. With $VKTX, the point is pivotal data: two large subcutaneous Phase 3 trials are fully enrolled, so the decisive question is what the efficacy and safety readouts show relative to the incretin benchmark, plus the start of the oral Phase 3. With $GPCR, the point is the Phase 3 transition and competitive positioning in the oral segment, supported by a balance sheet that removes near-term financing pressure. With $SKYE, the point is twofold and inseparable: the higher-dose expansion data that will show whether the mechanism can work better, and the financing situation that a micro-cap with runway only into Q4 2026 cannot avoid. In every case, the surrounding pipeline matters: a strong retatrutide, MariTide, amycretin or petrelintide readout can move the entire group’s benchmark, for better or worse.

Bottom line

The obesity drug market is one of the largest growth stories in healthcare, and the approved layer is a Novo Nordisk versus Eli Lilly duopoly. But for traders looking at clinical-stage exposure, three U.S.-listed names carry the most concentrated obesity story. $VKTX — Viking Therapeutics — is the most advanced pure-play, with a dual oral-and-injectable GLP-1/GIP program already in fully enrolled Phase 3 trials and roughly $603 million in cash. $GPCR — Structure Therapeutics — is the best-capitalized oral small-molecule bet, with strong Phase 2 data, a Nature Medicine publication, about $1.5 billion in cash and a Phase 3 start guided for Q3 2026. $SKYE — Skye Bioscience — is the differentiated, high-risk wildcard: a peripheral CB1 antibody with a missed monotherapy endpoint but an interesting combination and weight-regain signal, and a tight balance sheet that makes financing risk central. None of this is a recommendation to buy or sell anything. Each name carries real clinical, regulatory and financing risk, the competitive bar is high and still rising, and clinical-stage biotech remains a high-volatility sector where single binary events can move prices sharply in either direction. The value of a radar like this is to know what to watch, and why — not to predict the outcome.